CTRI/2012/03/002494Other3 期
A MULTICENTER, DOUBLE-MASKED, RANDOMIZED, PARALLEL ASSIGNMENT, STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE OF GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION MANUFACTURED BY INNOPHARMA INC. WITH RESPECT TO AZOPTâ?¢ (BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION) IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSIO
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 286
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Male and females 18 years of age or older, diagnosed with primary open-angle glaucoma or ocular hypertension (including pigment dispersion syndrome).
- •2.If of child bearing potential -
- •Must use a reliable means of contraception for the duration of the study or surgically sterilized.
- •Must have a negative pregnancy test.
- •Must be non-lactating
- •3.9 am IOP measurements >= 24 <= 36 mmHg, inclusive, in at least one eye, at two eligibility visits separated by one week
- •4.The IOP criteria to be met by the same eye
- •5.Visual Acuity of 6/24 or better(or its equivalent by logMAR) in both eyes
- •6.Gonioscopy angle of >= 3 in both eyes
- •7.Patients with a level of understanding and willingness to fully comply with all visits and study procedures scheduled by the study site as evidenced by written informed consent
排除标准
- •1.Patients with any form of glaucoma other than open-angle glaucoma
- •2.Patients with Schaffer angle grade 3 (overall, however occludable angles treated with patent iridectomy are allowed )
- •3.Patients with a cup/disc ratio greater than 0.8
- •4.Patients with severe central visual field loss
- •5.Best corrected VA score worse than 20/200 Snellen (equivalent to +1.0 log Mar)
- •6.Chronic, recurrent or severe inflammatory eye disease (blepharitis or clinically non-significant conjunctival hyperaemia allowed)
- •7.Clinically significant or progressive retinal disease or optic nerve disease from any cause apart from glaucoma
- •8.Other ocular pathology especially Fuchâ??s endothelial dystrophy, moderate to severe guttata, subjectively low endothelial cell count by slit lamp biomicrscopy or any abnormality preventing reliable applanation tonometry
- •9.Recent, current, or anticipated treatment with any medication that augments adrenergic
- •responses, or precludes use of an alpha-adrenergic agonist like MAO inhibitors.
- •10.History of hypersensitivity to oral or topical CAIs, sulfonamide drugs or to any
- •component of these medications or the study medications or ingredients
- •11.Contact lens use during the active treatment portion of the trial. However if patient agrees to avoid use of contact lens use 15 minutes before and after drug administration, such patient can be included
- •12.Active ocular allergies.
- •13.Conventional ocular surgery or laser surgery within the 3 months prior to visit 1.
- •14.Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.
- •15.Active ocular diseases or uncontrolled systemic disease. Patients requiring concomitant aggressive therapy with antihypertensives or steroids or patients on oral CAIs like acetazolamide or methazolamide. However patients on stable dose of antihypertensive therapy or stable doses of dermal or inhaled steroids can be allowed
- •16.Pregnant or nursing mothers and females of childbearing potential not practicing a
- •reliable and medically acceptable method of birth control
- •17.Participation in any study during past 30 days
- •18.Relative or employee of the treating investigator
研究者
相似试验
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CYCLOSPORINE OPHTHALMIC SOLUTION 0,010% COMPARED WITH ITS VEHICLE ADMINISTRATED QID FOR 3 MONTHS FOLLOWED BY A 9 MONTH OPEN-LABEL PHASE IN PATIENTS WITH ATOPIC KERATOCONJUNCTIVITIS - NDEUCTR2009-012446-23-ITALLERGAN INC124
进行中（未招募）
1 期
6-MONTHS EFFICACY AND SAFETY CLINICAL TRIAL FOLLOWED BY 6-MONTHS OF SAFETY EVALUATION OF CYCLOKAT® 1MG/ML (CICLOSPORIN) EYE DROPS, EMULSION ADMINISTERED ONCE DAILY IN ADULT PATIENTS WITH SEVERE DRY EYE DISEASE (DED)EUCTR2011-000160-97-BEOVAGALI Pharma S.A.252
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 2 PARALLEL ARM, VEHICLE CONTROLLED, 6-MONTH PHASE III TRIAL WITH A 6 MONTH OPEN LABEL TREATMENT SAFETY FOLLOW-UP PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF CYCLOKAT 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED ONCE DAILY IN ADULT PATIENTS WITH SEVERE DRY EYE DISEASE (DED) - NDSevere DED (Drye Eye Disease)MedDRA version: 13.1Level: PTClassification code 10013774Term: Dry eyeSystem Organ Class: 10015919 - Eye disordersMedDRA version: 13.1Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 10015919 - Eye disordersMedDRA version: 13.1Level: PTClassification code 10023350Term: Keratoconjunctivitis siccaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 13.1Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000160-97-ITOVAGALI PHARMA S.A.252
进行中（未招募）
不适用
6-MONTHS EFFICACY AND SAFETY CLINICAL TRIAL FOLLOWED BY 6-MONTHS OF SAFETY EVALUATION OF CYCLOKAT® 1MG/ML (CICLOSPORIN) EYE DROPS, EMULSION ADMINISTERED ONCE DAILY IN ADULT PATIENTS WITH SEVERE DRY EYE DISEASE (DED)Severe Dry Eye DiseaseMedDRA version: 14.0Level: PTClassification code 10013774Term: Dry eyeSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: PTClassification code 10023350Term: Keratoconjunctivitis siccaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000160-97-CZOVAGALI Pharma S.A.252
进行中（未招募）
不适用
6-MONTHS EFFICACY AND SAFETY CLINICAL TRIAL FOLLOWED BY 6-MONTHS OF SAFETY EVALUATION OF CYCLOKAT® 1MG/ML (CICLOSPORIN) EYE DROPS, EMULSION ADMINISTERED ONCE DAILY IN ADULT PATIENTS WITH SEVERE DRY EYE DISEASE (DED)EUCTR2011-000160-97-SEOVAGALI Pharma S.A.252